Evidence map›Paper›PMID 36995239›Full record

ArticleAntimicrobial agents and chemotherapy2023

Absorption, Metabolism, and Excretion of [

Vipul K Gupta, Gary Maier, Leanne Gasink, Amanda Ek, Mary Fudeman, Praveen Srivastava, Angela Talley

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. The oral penems and carbapenems.Clinical microbiology reviews · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Vipul K GuptaSpero Therapeutics, Inc., Cambridge, Massachusetts, USA.ORCID 0000-0002-8093-5126
Gary MaierMaier Metrics and Associates LLC, Worcester, Massachusetts, USA.
Leanne GasinkLBG Consulting, LLC, Wayne, Pennsylvania, USA.
Amanda EkTakeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Mary FudemanImmunoGen, Inc., Waltham, Massachusetts, USA.
Praveen SrivastavaNurix Therapeutics, Inc., San Francisco, California, USA.
Angela TalleySpero Therapeutics, Inc., Cambridge, Massachusetts, USA.
Spero Therapeutics (United States) · USImmunoGen (United States) · USNurix (United States) · USTakeda (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral prodrug of pharmacologically active moiety tebipenem (TBP), which is a carbapenem with activity against multidrug-resistant Gram-negative pathogens. Conversion from the prodrug to the active moiety, namely, TBP, occurs in the enterocytes of the gastrointestinal tract via intestinal esterases. The absorption, metabolism, and excretion in humans were evaluated, following the administration of a single oral dose of [

Indexed as

ProdrugsAdministration, OralCarbapenemsCarbon RadioisotopesChromatography, LiquidFecesHumansMaleTandem Mass SpectrometryCarbapenemsCarbon RadioisotopesL 084Prodrugsabsorptionexcretionmass balancemetabolismtebipenem

Identifiers

PMID36995239
PMCPMC10112213
OpenAlexW4361270474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.